News

As an old investing adage goes: Investors have lost more reaching for yield than at the point of a gun. That may sound a bit dramatic, but when you think of all the yield trap stocks -- high-yield

Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give investors

UnitedHealth Group (NYSE: UNH) used to be a safe stock to hang on to. Its financials looked impressive, the business got bigger, it boosted its dividend, and it looked like a no-brainer stock to

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading and fractional shares. Even with a modest sum, you can find quality

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as

Dividend yields are more than just an indication of how much income a stock will generate for investors. High yields are often a sign that a stock is trading hands at an attractive price point. When

Shares in Viking Therapeutics (NASDAQ: VKTX) rose by a whopping 44.9% in October, according to data provided by S&P Global Market Intelligence. The move occurred in three legs, and each one was

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has

Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, trading down around 60% from its 2022 high-water mark. The

I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and

The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.

What does

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and question marks

Being a big company comes with a lot of positives. But there are negatives, too. Some businesses end up imploding under their own weight because they face increased scrutiny and competition and

Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are both among the largest drugmakers in the world. The latter currently has the edge in this department, with a market cap of $141

A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to

UnitedHealth Group (NYSE: UNH) has been a top dividend stock to own for years. It has consistently provided investors with a reliable dividend, and it has made generous increases to the payout over

Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including

It isn't all that difficult to find high-yield dividend stocks -- say, those paying out at more than 4%. The real trick is finding a company that produces sufficient profitability and free cash flow

Verity & Verity, LLC disclosed in its Oct. 21, 2025, SEC filing a purchase of 907,855 shares of Pfizer Inc. valued at an estimated $22.41 million for the quarter ended Sep. 30, 2025.

According to a

Some might view UnitedHealth Group (NYSE: UNH) as a stock and a company in retreat. UnitedHealth's shares have plunged more than 40% below the high set in the fourth quarter of 2024. The health

What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock. One that is trading at attractive levels is even more preferable. Excellent dividend payers